Sun Yuan-Dong, Zhang Hao, Chen Ye-Qiang, Wu Chun-Xue, Zhang Jian-Bo, Xu Hui-Rong, Liu Jing-Zhou, Han Jian-Jun
Interventional Medicine Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Ji'nan, China.
Maternal and Child Health Care Hospital of Shandong Province, Ji'nan, China.
Front Oncol. 2020 Dec 15;10:572418. doi: 10.3389/fonc.2020.572418. eCollection 2020.
HMGB1 is an important mediator of inflammation during ischemia-reperfusion injury on organs. The serum expression of HMGB1 was increased significantly on the 1st day after TACE and decreased significantly which was lower on the 30th day after TACE. Tumor markers of post-DEB-TACE decreased significantly. The correlational analysis showed that patients with low HMGB1 expression had lower risks of fever and liver injury compared those with the higher expression, while the ORR is relatively worse. Patients with lower expression of HMGB1 had longer PFS, better efficacy, and higher quality of life. With the high post-expression, the low expression had lower incidence of fever and liver injury too. There was no statistical difference in the one-year survival among the different groups. The quality of life of all patients was improved significantly. The over-expression of HMGB1 in LMCRC is an adverse prognostic feature and a positive predictor of response to TACE.
HMGB1是器官缺血再灌注损伤期间炎症的重要介质。TACE术后第1天血清HMGB1表达显著升高，第30天显著下降，低于TACE术后第1天。DEB-TACE术后肿瘤标志物显著下降。相关性分析显示，与高表达患者相比，HMGB1低表达患者发热和肝损伤风险较低，而客观缓解率相对较差。HMGB1低表达患者无进展生存期更长、疗效更好、生活质量更高。与高表达相比，低表达患者发热和肝损伤发生率也较低。不同组之间1年生存率无统计学差异。所有患者生活质量均显著改善。HMGB1在LMCRC中的过表达是不良预后特征及TACE反应的阳性预测指标。
